EdiGene is a genome-editing company, possessing efficient genome-editing techniques, advanced high-throughput genetic screening platform, and ready-made knock-out cell lines. EdiGene dedicates to server the biomedical companies, diagnostic companies, and R&D groups with rich genome editing experience.
The simplicity of the CRISPR/Cas9 system of genome engineering has opened up the possibility of performing genome-wide targeted mutagenesis in cell lines, enabling screening for cellular phenotypes resulting from genetic aberrations1.The ability of CRISPR to generate genetic loss of function mutations not only increases the magnitude of any effect over currently employed RNAi techniques, but allows analysis over longer periods of time which can be critical for certain phenotypes1.
Integrating the Loss of Function High-throughput Genetic Screening and CRISPR/Cas9 technology, EdiGene can demonstrate unknown gene-drug connection, discover new disease related drug target, and analyze gene function. EdiGene has the rich experience in high throughput genome editing and own a series of libraries and sub-libraries, and can generate customized libraries to meet special need for high throughput screens to accelerate drug discovery and clinical trials.
EdiGene Biotechnology Inc. has not received any reviews.
EdiGene Biotechnology Inc. has not received any endorsements.